MedCity News
Grifols reaches across the Atlantic and shells out $450M in a pair of M&A deals
Grifols s acquisition of GigaGen comes as the startup s Covid-19 antibody drug is set to start Phase 1 testing. Barcelona-based Grifols says GigaGen’s technology could also help it expand to engineered antibody therapies.
Shares0
Plasma is the lifeblood of Grifols, serving as the raw material for the biological medicines that generate most of the company’s revenue. But the Barcelona-based firm has eyed expansion beyond plasma-derived products and its acquisition of GigaGen offers the company the opportunity to add antibody drugs to its pipeline.
Paying close attention to social determinants of health, like ability to drive or proximity to a grocery store, can also help predict who is at highest risk of being food insecure which, in turn, can help a plan know which resources to offer to those members.
MedCity News
Cognito looks to light, sound for potential Alzheimer’s treatment
Digital health startup Cognito shared results of a Phase 2 trial of its device, intended to treat Alzheimer’s disease using gamma frequency light and sound. Based on the results, it plans to launch a pivotal study of the treatment.
Shares0
In a sea of failed Alzheimer’s treatments, a digital health startup is hoping to find answers in a noninvasive treatment using light and sound.
Cognito was founded by MIT Professors Li-Huei Tsai and Ed Boyden. The company was spun out of research where they found they could reduce amyloid plaques in mice by exposing them to light flickering at a certain frequency. Now, they’re seeing if the treatment holds promise for Alzheimer’s patients.